Oric Pharmaceuticals (NasdaqGS:ORIC) Update / briefing Transcript

ORIC Pharmaceuticals Conference Call Summary Company Overview - Company: ORIC Pharmaceuticals (NasdaqGS:ORIC) - Focus: Development of rinzimetostat, a PRC2 inhibitor for prostate cancer, and enozertinib, an EGFR inhibitor for non-small cell lung cancer, in collaboration with Bayer and Johnson & Johnson [4][6] Key Points and Arguments Clinical Data and Pipeline - Rinzimetostat: A next-generation PRC2 inhibitor designed for superior potency and a 20-hour clinical half-life, minimizing toxicity [5] - Phase III Trial: The first phase III trial, named Himalayas-1, will target post-abiraterone metastatic CRPC, a market worth $3.5 billion annually in the U.S. [6][10] - Efficacy: Rinzimetostat shows competitive efficacy with early landmark radiographic progression-free survival (RPFS) rates and a favorable safety profile compared to existing therapies [5][8][10] Competitive Landscape - Current Therapies: Existing treatments like enzalutamide and docetaxel show median RPFS of 6-9 months, while rinzimetostat aims for a double-digit RPFS [6][7] - Comparison with Meverometostat: Rinzimetostat's early data suggests it may outperform meverometostat in terms of safety and efficacy, with a cleaner safety profile [7][9][36] Safety Profile - Adverse Events: Most adverse events for rinzimetostat in combination with darolutamide are grade 1 or 2, with a significantly lower incidence of severe events compared to competitors [9][25][36] - Patient Population: The trial population is more heavily pretreated than competitors, with a median baseline PSA of 26 for the 400 mg dose group, indicating a more advanced disease state [24][72] Market Potential - Addressable Market: The U.S. market for post-abiraterone mCRPC is estimated at over $3.5 billion, with potential expansion into other prostate cancer indications, increasing the total market to over $10 billion [10][41] - Physician Insights: Market research indicates a strong preference for rinzimetostat due to its safety profile, potentially capturing 80% of the PRC2 class market share [49] Future Development - Additional Trials: Plans for future phase III trials in other indications, including metastatic castration-sensitive prostate cancer and colorectal cancer, are underway [42][50] - FDA Engagement: Regular communication with the FDA is ongoing, with an end-of-phase I meeting planned to finalize the trial design and RP3D selection [65][66] Other Important Content - Preclinical Data: Rinzimetostat has shown superior potency in preclinical studies compared to first-generation PRC2 inhibitors, supporting its potential as a best-in-class therapy [11][12] - Mechanistic Rationale: The drug's ability to reverse epigenetic reprogramming in prostate cancer cells enhances its therapeutic potential when combined with AR inhibitors [14][15] This summary encapsulates the critical insights from the ORIC Pharmaceuticals conference call, highlighting the company's strategic focus on rinzimetostat and its promising clinical data, competitive positioning, and market potential.